A selection of prognostic scores proposed for MZLs
| Score . | Subtype . | Parameters . | Categories . |
|---|---|---|---|
| IIL score9 | SMZL | Hemoglobin <12 g/dL LDH > ULN Albumin <3.5 g/dL | Low-risk (0 factor): 5-y CSS 88% Intermediate-risk (1 factor): 5-y CSS 73% High-risk: (2-3 factors): 5-y CSS 50% |
| HPLL score76 | SMZL | Hemoglobin Platelets LDH Extrahilar lymphadenopathy | Low-risk (0 factor): 5-y LSS 94% Intermediate-risk (1 factor): 5-y LSS 78% High-risk group (2-3 factors): 5-y LSS 69% |
| HPLL score simplified11 | SMZL | Hemoglobin <9.5 g/dL Platelets <80 × 109/l LDH > ULN Extrahilar lymphadenopathy | Group A (0 factor): 5-y LSS 95% Group B (1-2 factors): 5-y LSS 87% Group C (3-4 factors): 5-y LSS 68% |
| MALT-IPI10 | EMZL | Age >70 y Stage III/IV LDH > ULN | Low-risk (0 factor): 5-y EFS 70% Intermediate-risk (1 factor): 5-y EFS 78% High-risk group (2-3 factors): 5-y EFS 69 |
| POD24 (early POD)12,13 | EMZL SMZL Disseminated MZL | Lymphoma progression within 24 mo from diagnosis (yes or no) | FIL study (all MZL)12 : No: 3-y OS 88% Yes: 3-y OS 53% IELSG study (EMZL)13 : No: 10-y OS 85% Yes: 10-y OS 64% |
| Score . | Subtype . | Parameters . | Categories . |
|---|---|---|---|
| IIL score9 | SMZL | Hemoglobin <12 g/dL LDH > ULN Albumin <3.5 g/dL | Low-risk (0 factor): 5-y CSS 88% Intermediate-risk (1 factor): 5-y CSS 73% High-risk: (2-3 factors): 5-y CSS 50% |
| HPLL score76 | SMZL | Hemoglobin Platelets LDH Extrahilar lymphadenopathy | Low-risk (0 factor): 5-y LSS 94% Intermediate-risk (1 factor): 5-y LSS 78% High-risk group (2-3 factors): 5-y LSS 69% |
| HPLL score simplified11 | SMZL | Hemoglobin <9.5 g/dL Platelets <80 × 109/l LDH > ULN Extrahilar lymphadenopathy | Group A (0 factor): 5-y LSS 95% Group B (1-2 factors): 5-y LSS 87% Group C (3-4 factors): 5-y LSS 68% |
| MALT-IPI10 | EMZL | Age >70 y Stage III/IV LDH > ULN | Low-risk (0 factor): 5-y EFS 70% Intermediate-risk (1 factor): 5-y EFS 78% High-risk group (2-3 factors): 5-y EFS 69 |
| POD24 (early POD)12,13 | EMZL SMZL Disseminated MZL | Lymphoma progression within 24 mo from diagnosis (yes or no) | FIL study (all MZL)12 : No: 3-y OS 88% Yes: 3-y OS 53% IELSG study (EMZL)13 : No: 10-y OS 85% Yes: 10-y OS 64% |
CSS, cause-specific survival; EFS, event-free survival; HPLL, hemoglobin, platelet count, LDH, extrahilar lymphadenopathy; IIL, Integruppo Italiano Linfomi; LSS, lymphoma-specific survival; POD, progression of disease; ULN, upper level of normal.